Retisert (fluocinolone acetonide intravitreal implant) / EyePoint Pharma, Bausch Health  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma
NCT00543296: Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment

Completed
4
21
US
0.59 mg Fluocinolone Acetonide implant, Retisert
Duke University, Bausch & Lomb Incorporated
Uveitis
07/07
07/07
NCT00720928: Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease

Unknown status
4
15
RoW
flucinolone acetonide, RETISERT
Asan Medical Center, Samsung Medical Center, Seoul National University Hospital, Kyunghee University Medical Center
Ocular Behcet's Disease,, Non-Infectious Uveitis, Refractory Uveitis
12/09
05/10

Download Options